-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Sunday, Incyte Taps QIAGEN And Illumina Technology To Advance Precision Diagnostics For CALR-Driven Myeloproliferative Neoplasms

Benzinga·06/16/2025 07:57:11
Listen to the news
  • QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies
  • Companion diagnostic to identify key disease-causing mutations in patients with MPNs, with an initial focus on mutant CALR the second most common driver of MPNs
  • Panel to be validated on Illumina NextSeq 550Dx platform for use with whole blood samples
  • Partnership supports Incyte's extensive portfolio in myeloproliferative neoplasms, including INCA033989, and enhances QIAGEN's onco-hematology diagnostics pipeline